Clinical and pharmacological properties of incobotulinumtoxinA and its use in neurological disorders

Overview of attention for article published in Drug Design, Development and Therapy, April 2015

Altmetric Badge

About this Attention Score

Above-average Attention Score compared to outputs of the same age (54th percentile)
Above-average Attention Score compared to outputs of the same age and source (60th percentile)

Mentioned by

policy: 1 policy source

Citations

dimensions_citation: 28 Dimensions

Readers on

mendeley: 118 Mendeley

Summary Policy documents Dimensions citations

So far, Dimensions has found 28 publications that cite this research output.

28

The most recent citing publications are shown below. View all 28 publications that cite this research output on Dimensions.

Improvement in Quality-of-Life-Related Outcomes Following Treatment with IncobotulinumtoxinA in Adults with Limb Spasticity: A Pooled Analysis

Article in Toxins (December 2023)

SAMCEP Society consensus on the treatment of upper facial lines with botulinum neurotoxin type A: A tailored approach

Article in Journal of Cosmetic Dermatology (July 2023)

Effectiveness and Safety of Intracavernosal IncobotulinumtoxinA (Xeomin®) 100 U as an Add-on Therapy to Standard Pharmacological Treatment for Difficult-to-Treat Erectile Dysfunction: A Case Series

Article in Toxins (April 2022)